Literature DB >> 33950214

PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA.

Melissa F Adasme1, Katja L Linnemann1, Sarah Naomi Bolz1, Florian Kaiser2, Sebastian Salentin1, V Joachim Haupt2, Michael Schroeder1.   

Abstract

With the growth of protein structure data, the analysis of molecular interactions between ligands and their target molecules is gaining importance. PLIP, the protein-ligand interaction profiler, detects and visualises these interactions and provides data in formats suitable for further processing. PLIP has proven very successful in applications ranging from the characterisation of docking experiments to the assessment of novel ligand-protein complexes. Besides ligand-protein interactions, interactions with DNA and RNA play a vital role in many applications, such as drugs targeting DNA or RNA-binding proteins. To date, over 7% of all 3D structures in the Protein Data Bank include DNA or RNA. Therefore, we extended PLIP to encompass these important molecules. We demonstrate the power of this extension with examples of a cancer drug binding to a DNA target, and an RNA-protein complex central to a neurological disease. PLIP is available online at https://plip-tool.biotec.tu-dresden.de and as open source code. So far, the engine has served over a million queries and the source code has been downloaded several thousand times.
© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2021        PMID: 33950214      PMCID: PMC8262720          DOI: 10.1093/nar/gkab294

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


MOTIVATION

The Protein Data Bank (PDB) (1) is continuously growing and recent advances in structure prediction and experimental methods such as cryoEM will further accelerate this growth. The vast majority of protein structures in PDB contain ligands and therefore it is important to understand how these ligands interact with their targets. PLIP, the protein–ligand interaction profiler (2), addresses this need. It detects hydrogen bonds, hydrophobic contacts, π-stacking, π-cation interactions, salt bridges, water bridges, metal complexes and halogen bonds between ligands and targets. PLIP is easy to use as it requires only a PDB ID or a PDB file as input, it has been running reliably and continuously for 5 years, and it is transparent with all the source code published on GitHub. PLIP 2021 constitutes a major update with added support for nucleic acids, more flexibility by adjustable thresholds, mode and model selection and a more functional and modern design for increased usability. The two main cases for PLIP are the analysis and visualisation of docking results and the in-depth study of existing structures. Elfiky uses PLIP to show docking results of a drug repurposing screen for COVID-19 (3). Furlan et al. run an inverse docking screen to identify targets of curcumin, a natural compound (4). They show PLIP interactions for a human folate receptor and a phosphodiesterase. PLIP is used on existing structures by Soliman et al. to study antibody recognition of tumour-associated glycans (5) and by Kumar et al. to survey specific cation–π interactions (6).

PLIP WEB SERVER AND COMMAND-LINE

The PLIP web server provides an easy-to-use interface (Figure 1), which takes as input either a PDB ID or a custom structure in PDB format (e.g. result files from docking or molecular dynamics software). Moreover, the advanced options in the input section allow the users to modify the default settings of PLIP according to their special requirements, such as adjustments to thresholds for the detection of interactions, the consideration of modified residues, the specification of which model to use in multi-model structures, the detection of intra- and inter-chain interactions and the treatment of nucleic acids.
Figure 1.

PLIP web tool result page. On the left is a menu for ligands and binding sites, in the middle an image of a selected binding site and on the right a table with details of the interactions.

PLIP web tool result page. On the left is a menu for ligands and binding sites, in the middle an image of a selected binding site and on the right a table with details of the interactions. Given an input structure, a list with all binding sites and binding ligands is provided on the left panel of the web tool (see Figure 1). On the right panel, the results for all binding sites are displayed. For each binding site, PLIP offers atom-level binding information, an image, a 3D interactive visualisation with JSmol and a PyMOL session file. In case a manual inspection or subsequent processing is necessary, a parsable XML or RST file with interaction data is available. The web server is based on the PLIP command-line tools version 2.2.0, which is publicly available at github.com/pharmai/plip under the GNU GPLv2 licence. The command-line tool enables high-throughput computation of protein structures and can be integrated into analysis pipelines using the machine-readable result files. PLIP is easy to use for high-throughput and high-performance computing, as it is virtualised and bundled with all necessary software in Docker and Singularity containers.

PLIP FOR DNA AND RNA

PLIP’s main focus so far was the detection of interactions between small molecules and proteins. However, with the constant growth of nucleic acid structure data, a large proportion of over 7% of the PDB (12460 structures) contains DNA and RNA (Figure 2). Of these, the majority are protein–nucleic acid complexes (8837) and the rest are mostly DNA or RNA only.
Figure 2.

Nucleic acid structures growth in PDB. Number of nucleic acid structures released annually since 2000 and the total aggregated structures.

Nucleic acid structures growth in PDB. Number of nucleic acid structures released annually since 2000 and the total aggregated structures. Studying the interactions of nucleic acids to ligands and to proteins is important. DNA/RNA can act, for instance, as a target for novel cancer drugs such as the drug XR5944 (7) and as a ligand to proteins involved in disease such as the protein FUS, which is implicated in the neurological disorder ALS (8).

Protein–RNA interaction: FUS binding UGGUG

FUS is a nuclear RNA-binding protein involved in RNA metabolism. It can undergo liquid–liquid phase separation, forming membraneless organelles (9–11). Aberrant phase transition of FUS into pathological solid aggregates has been linked to neurodegenerative diseases (12,13). Recent studies have shown that high RNA concentrations prevent phase separation of FUS (8) and mutations in FUS can cause aberrant phase separation (14). Loughlin et al. have solved the structure of FUS bound to RNA (15). We applied the new version of PLIP to identify the interactions between the zinc finger of FUS as receptor and the RNA sequence UGGUG as ligand (Figure 3A). PLIP detects π-stacking interactions of the central Phe438 with the flanking G2 and G3 of the RNA. G2 is additionally anchored by a π-cation contact with Arg422, a salt bridge with Asp425, and several hydrogen bonds with Arg422, Trp440, Ser439 and Gln420. Multiple sequence-specific hydrogen bonds are also formed between G3 and Phe438, Arg441 and Met436. U4 binds the FUS zinc finger via hydrogen bonds with Asn435, Gln446 and Asn445. The zinc finger recognises U1 by a hydrophobic interaction. Illuminating the RNA-binding mode of FUS paves the way for a deeper understanding of the mechanisms that lead to the formation of solid aggregates in neurodegenerative diseases.
Figure 3.

Examples. (A) FUS binding the UGGUG (PDB ID: 6G99), (B) XR5944 binding the TFF1 estrogen response element (PDB ID: 2MG8) and (C) GTP binds RNA polymerase II and DNA/RNA of the elongation complex (PDB ID: 2E2H). Ligands are shown in orange and receptors in blue, green or purple gray. Protein residues are labeled in black and DNA/RNA bases in red.

Examples. (A) FUS binding the UGGUG (PDB ID: 6G99), (B) XR5944 binding the TFF1 estrogen response element (PDB ID: 2MG8) and (C) GTP binds RNA polymerase II and DNA/RNA of the elongation complex (PDB ID: 2E2H). Ligands are shown in orange and receptors in blue, green or purple gray. Protein residues are labeled in black and DNA/RNA bases in red.

Small molecule–DNA interaction: XR5944 binding estrogen response element

The cancer drug candidate XR5944 is a DNA bis-intercalator that strongly binds DNA in a sequence-specific manner (7,16–18). Because of its structural similarity to other topoisomerase inhibitors, XR5944 was originally thought to inhibit topoisomerase I and II (19), but was later shown to be a DNA transcription inhibitor instead (20,21). Interestingly, XR5944 specifically recognises the estrogen response element (ERE), the target DNA sequence of estrogen receptor-α (ERα), making it a promising drug for the treatment of ERα-positive breast cancer (18,22,23). EREs are present in the regulatory region of several genes, including Trefoil factor 1 (TFF1). Lin et al. published the structure of two XR5944 molecules bound to the naturally occurring DNA TFF1-ERE (18). Thus, TFF1 acts as receptor and XR5944 as ligand, which PLIP treats accordingly (Figure 3B). PLIP identifies parallel π-stacking interactions between the phenazine rings of the XR5944 molecules and the flanking base pairs. In addition, it detects several hydrophobic interactions at the intercalation sites. Furthermore, the carboxamide aminoalkyl linkers of the XR5944 molecules form site-specific hydrogen bonds with the base pairs in the major groove. The non-covalent interactions formed by XR5944 with the TFF1-ERE determine its binding mode and sequence specificity. Uncovering these interactions provides a structural basis for the rational design of drugs that target EREs.

Small molecule–protein/DNA/RNA interaction: GTP binding RNA polymerase II and the DNA/RNA strands

Transcription, the synthesis of RNA from a DNA template, is one of the most important steps in the control of cell growth and differentiation (24,25). During transcription, the information in a strand of DNA is copied into a new molecule of mRNA, mainly carried out by the enzyme RNA polymerase II and a number of accessory proteins called transcription factors (26). The RNA polymerase begins mRNA synthesis by unwinding the DNA helix and adding complementary bases to the RNA strand (elongation). The substrates for RNA synthesis are the four nucleoside triphosphates ATP, GTP, CTP and UTP. Cleavage of the high-energy phosphate bond between the phosphate groups in the nucleoside triphosphate structure provides the necessary energy for the addition of nucleotides into the growing RNA chain (27). Wang et al. obtained the X-ray structure revealing the transcribing complex in the ‘post-translocation’ state with the nucleotide added to the RNA transcript (28). Figure 3C shows how PLIP analyses such a complex and characterises the binding of GTP (orange) to the RNA polymerase (purple grey), RNA strand (green) and DNA strand (blue), all at the same time. The guanine group in GTP binds to the DNA strand with three hydrogen bonds and to the RNA strand via parallel π-stacking and one hydrogen bond. Moreover, the phosphate groups in GTP bind to the RNA polymerase residues via a salt bridge and a metal complex. The characterisation of the GTP binding mode in the elongation complex provides a structural understanding of the transcription mechanism.

PLIP algorithm for DNA/RNA detection

PLIP uses four steps to detect and report the relevant interactions of a complex: structure preparation, functional characterisation and rule-based matching and filtering of interactions. In the preparation step, the input structure is hydrogenated and the ligands are extracted along with their binding sites. If the advanced option for analysing DNA or RNA as receptor is selected, PLIP will automatically detect the nucleic acid residues as part of the receptor and exclude them from the ligand molecules. The RNA and DNA residues to be considered are detected by their name U, A, C, G and DT, DA, DC, DG, respectively. After the correct detection of receptor and ligands, PLIP continues with the subsequent interaction detection and visualisation as previously described in (2).

PLIP AND OTHER TOOLS

There are a number of tools (29–37) analysing ligand–target interactions, but apart from one, they have a different focus and therefore suffer from some limitations: (29–33) detect only a limited set of interaction types and do not offer 3D visualisation, (34) requires extensive preparation of input files, (38) is only commercially available and (35,36) are limited to binary interaction fingerprints and do not cover DNA and RNA. Arpeggio (37) is most closely related to PLIP offering comparable functionality except for flexible adjustment of thresholds.

CONCLUSION

Interactions between nucleic acids and small molecules play a crucial role in various biological processes and have a strong impact on drug discovery. In that regard, the PLIP web tool has been adapted to recognise nucleic acid molecules as receptors and provide a comprehensive analysis and visualisation of non-covalent interactions with a one-click loading of structures. Moreover, its novel design displays a user-friendly platform, which facilitates the intuitive use of the tool’s features and exploration of the results for a better understanding of the biological processes behind the binding mechanism. Furthermore, the availability of PLIP source code enables local batch processing, customisation of the algorithm for special applications as well as active development of the tool in the community.
  37 in total

1.  The Solution Structure of FUS Bound to RNA Reveals a Bipartite Mode of RNA Recognition with Both Sequence and Shape Specificity.

Authors:  Fionna E Loughlin; Peter J Lukavsky; Tamara Kazeeva; Stefan Reber; Eva-Maria Hock; Martino Colombo; Christine Von Schroetter; Phillip Pauli; Antoine Cléry; Oliver Mühlemann; Magdalini Polymenidou; Marc-David Ruepp; Frédéric H-T Allain
Journal:  Mol Cell       Date:  2018-12-20       Impact factor: 17.970

2.  XR5944: A potent inhibitor of estrogen receptors.

Authors:  Chandanamali Punchihewa; Adrian De Alba; Neil Sidell; Danzhou Yang
Journal:  Mol Cancer Ther       Date:  2007-01-11       Impact factor: 6.261

Review 3.  Mechanisms and Consequences of Macromolecular Phase Separation.

Authors:  Louis-Philippe Bergeron-Sandoval; Nozhat Safaee; Stephen W Michnick
Journal:  Cell       Date:  2016-05-19       Impact factor: 41.582

Review 4.  Antibody recognition of aberrant glycosylation on the surface of cancer cells.

Authors:  Caroline Soliman; Elizabeth Yuriev; Paul A Ramsland
Journal:  Curr Opin Struct Biol       Date:  2016-11-04       Impact factor: 6.809

5.  Biological characterization of MLN944: a potent DNA binding agent.

Authors:  Darshan S Sappal; A Kathleen McClendon; James A Fleming; Vala Thoroddsen; Kelly Connolly; Corinne Reimer; Ronald K Blackman; Christine E Bulawa; Neil Osheroff; Peter Charlton; Laura A Rudolph-Owen
Journal:  Mol Cancer Ther       Date:  2004-01       Impact factor: 6.261

Review 6.  Protein Phase Separation: A New Phase in Cell Biology.

Authors:  Steven Boeynaems; Simon Alberti; Nicolas L Fawzi; Tanja Mittag; Magdalini Polymenidou; Frederic Rousseau; Joost Schymkowitz; James Shorter; Benjamin Wolozin; Ludo Van Den Bosch; Peter Tompa; Monika Fuxreiter
Journal:  Trends Cell Biol       Date:  2018-03-27       Impact factor: 20.808

7.  A Molecular Grammar Governing the Driving Forces for Phase Separation of Prion-like RNA Binding Proteins.

Authors:  Jie Wang; Jeong-Mo Choi; Alex S Holehouse; Hyun O Lee; Xiaojie Zhang; Marcus Jahnel; Shovamayee Maharana; Régis Lemaitre; Andrei Pozniakovsky; David Drechsel; Ina Poser; Rohit V Pappu; Simon Alberti; Anthony A Hyman
Journal:  Cell       Date:  2018-06-28       Impact factor: 41.582

8.  PLIP: fully automated protein-ligand interaction profiler.

Authors:  Sebastian Salentin; Sven Schreiber; V Joachim Haupt; Melissa F Adasme; Michael Schroeder
Journal:  Nucleic Acids Res       Date:  2015-04-14       Impact factor: 16.971

9.  Solution structure of a 2:1 complex of anticancer drug XR5944 with TFF1 estrogen response element: insights into DNA recognition by a bis-intercalator.

Authors:  Clement Lin; Raveendra I Mathad; Zhenjiang Zhang; Neil Sidell; Danzhou Yang
Journal:  Nucleic Acids Res       Date:  2014-04-07       Impact factor: 16.971

10.  PyPLIF: Python-based Protein-Ligand Interaction Fingerprinting.

Authors:  Muhammad Radifar; Nunung Yuniarti; Enade Perdana Istyastono
Journal:  Bioinformation       Date:  2013-03-19
View more
  74 in total

1.  Evaluating In Silico the Potential Health and Environmental Benefits of Houseplant Volatile Organic Compounds for an Emerging 'Indoor Forest Bathing' Approach.

Authors:  Valentina Roviello; Pasqualina Liana Scognamiglio; Ugo Caruso; Caterina Vicidomini; Giovanni N Roviello
Journal:  Int J Environ Res Public Health       Date:  2021-12-27       Impact factor: 3.390

2.  Anti-epileptic Kunitz-like peptides discovered in the branching coral Acropora digitifera through transcriptomic analysis.

Authors:  Hanbin Chen; Shirley Weng In Siu; Clarence Tsun Ting Wong; Jianwen Qiu; Alex Kwok-Kuen Cheung; Simon Ming Yuen Lee
Journal:  Arch Toxicol       Date:  2022-05-23       Impact factor: 6.168

3.  In silico investigation of Alsin RLD conformational dynamics and phosphoinositides binding mechanism.

Authors:  Marco Cannariato; Marcello Miceli; Marco Agostino Deriu
Journal:  PLoS One       Date:  2022-07-18       Impact factor: 3.752

4.  Molecular characterization and determination of the biochemical properties of cathepsin L of Trichinella spiralis.

Authors:  Ruo Dan Liu; Xiang Yu Meng; Chen Le Li; Shao Rong Long; Jing Cui; Zhong Quan Wang
Journal:  Vet Res       Date:  2022-06-23       Impact factor: 3.829

5.  Coupling of acceptor-substituted diazo compounds and tertiary thioamides: synthesis of enamino carbonyl compounds and their pharmacological evaluation.

Authors:  Jim Secka; Arpan Pal; Francis A Acquah; Blaine H M Mooers; Anand B Karki; Dania Mahjoub; Mohamed K Fakhr; David R Wallace; Takuya Okada; Naoki Toyooka; Adama Kuta; Naga Koduri; Deacon Herndon; Kenneth P Roberts; Zhiguo Wang; Bethany Hileman; Nisha Rajagopal; Syed R Hussaini
Journal:  RSC Adv       Date:  2022-07-05       Impact factor: 4.036

6.  The Relationship between the IC50 Values and the Apparent Inhibition Constant in the Study of Inhibitors of Tyrosinase Diphenolase Activity Helps Confirm the Mechanism of Inhibition.

Authors:  Pablo Garcia-Molina; Francisco Garcia-Molina; Jose Antonio Teruel-Puche; Jose Neptuno Rodriguez-Lopez; Francisco Garcia-Canovas; Jose Luis Muñoz-Muñoz
Journal:  Molecules       Date:  2022-05-13       Impact factor: 4.927

7.  A New Variant of Mutational and Polymorphic Signatures in the ERG11 Gene of Fluconazole-Resistant Candida albicans.

Authors:  Arome Solomon Odiba; Olanrewaju Ayodeji Durojaye; Ifeoma Maureen Ezeonu; Anthony Christian Mgbeahuruike; Bennett Chima Nwanguma
Journal:  Infect Drug Resist       Date:  2022-06-17       Impact factor: 4.177

8.  Mixed Ligand Mononuclear Copper(II) Complex as a Promising Anticancer Agent: Interaction Studies with DNA/HSA, Molecular Docking, and In Vitro Cytotoxicity Studies.

Authors:  Kumudini Paliwal; Paramita Haldar; P K Sudhadevi Antharjanam; Manjuri Kumar
Journal:  ACS Omega       Date:  2022-06-13

9.  In situ generation of a Zwitterionic fluorescent probe for detection of human serum albumin protein.

Authors:  Rajib Choudhury; Arun K Sharma; Pratikshya Paudel; Preston Wilson; Andres Barboza Pereira
Journal:  Anal Biochem       Date:  2022-03-04       Impact factor: 3.191

10.  Design, Synthesis, Biological Evaluation and Silico Prediction of Novel Sinomenine Derivatives.

Authors:  Shoujie Li; Mingjie Gao; Xin Nian; Liyu Zhang; Jinjie Li; Dongmei Cui; Chen Zhang; Changqi Zhao
Journal:  Molecules       Date:  2021-06-07       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.